Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca B Regulatory News (SVCT)

Share Price Information for Seneca B (SVCT)

Share Price is delayed by 15 minutes
Get Live Data
44.00    0.00 (0.00%)
Bid:
43.00
Ask:
45.00
Spread: 2.00 (4.651%)
Market Cap: £14.56m
SVCT Live PriceLast checked at - London Stock Exchange

Intraday Seneca B Share Chart

Directorate Changes

18 May 2023 13:38

Directorate Changes

Directorate Changes

Seneca Growth Capital VCT Plc (the "Company")

18 May 2023

Appointment of Non-Executive Director and Appointment of Chair of the Audit Committee

Non-Executive Director

The Board of Seneca Growth Capital VCT Plc is delighted to announce that Mary Anne Cordeiro was today appointed to the Board as non-executive Director of the Company. Mary Anne has also joined the Company’s Audit Committee.

Mary Anne brings to the Board extensive knowledge of both the VCT and growth capital investment sectors, having been an advisor to or executive of innovative companies in the healthcare and technology sectors for over twenty years. Mary Anne has served as a non-executive Director of Albion Technology & General VCT Plc (“AATG”) from 2013 until 2023, following its merger with Albion Income & Growth VCT Plc where she had served as a non-executive Director from 2004. Having served nine years as non-executive Director, more recently as Senior Independent Director and Chair of the Remuneration Committee, Mary Anne is retiring from the AATG Board today. Mary Anne is also the Founder and Managing Director of Science to Business Limited which specialises in advising medical technology businesses on fundraising and commercialisation strategy. Prior to this Mary Anne had a fifteen-year career in international corporate finance as a M&A Investment Banker at Goldman Sachs International Limited, Vice President at Bankers Trust Company and Managing Director of Paribas’ Financial Institutions Group. Mary Anne holds a MA (Hons) in Chemistry from the University of Oxford and is a member of the University of Oxford’s Department of Chemistry Development Board.

Mary Anne will stand for election at the Annual General Meeting of the Company to be held in 2024. There is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 in relation to the appointment of Mary Anne.

Chair of the Audit Committee

We are also pleased to announce that further to Richard Roth’s retirement from the Board , with effect from today’s Annual General Meeting, Alex Clarkson has been appointed as Chair of the Audit Committee. Alex qualified as a Chartered Accountant with PwC in 1998 and has served as an independent non-executive Director of the Company and been a member of the Audit Committee since 2019.

These appointments are in accordance with the Board’s succession plans as outlined in the Company’s 2022 Annual Report, which was published on 21 April 2023.

Board Composition

The Board maintains its composition of four non-executive Directors, comprising three independent non-executive Directors and one representative of the Company’s Investment Manager, Seneca Partners Limited.

The Company’s Board is mindful of the new Listing Rule requirements which came into force for accounting periods starting after 1 April 2022 which require the Company to either comply with, or explain its non-compliance with, new rules intended to improve the diversity of publicly listed Boards.

The new rules seek to achieve 40% Board representation from women, one senior board position to be held by a woman and one Director to be from an ethnic minority background. Whilst the Company does not yet fully comply with the requirements, the Board will continue to work to improve the Board’s composition, providing suitable candidates possess the key skills and experience required for the position. The Board will always appoint the best person for the job. It will not discriminate on the grounds of gender, race, ethnicity, religion, sexual orientation, age or physical ability. The Board also fully supports the aims of the Hampton Alexander Report, the Parker Review and the renewed focus and emphasis on diversity in the AIC Code of Corporate Governance.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Date   Source Headline
28th Apr 202110:52 amGNWIssue of Equity and Total Voting Rights
1st Apr 20215:29 pmGNWDirector/PDMR Shareholding
1st Apr 202111:36 amGNWIssue of Equity and TVR
31st Mar 20217:00 amGNWNet Asset Value(s)
29th Mar 20215:12 pmGNWResult of AGM
4th Mar 20215:26 pmGNWDirector/PDMR Shareholding
2nd Mar 202112:50 pmGNWIssue of Equity and Total Voting Rights
24th Feb 20211:49 pmGNWIssue of Prospectus
23rd Feb 20217:00 amGNWFinal Results and NAV Update
18th Feb 20217:00 amGNWDividend Declaration
10th Dec 20203:57 pmGNWDirector/PDMR Shareholding
9th Dec 20203:49 pmGNWIssue of Equity and Total Voting Rights
5th Nov 20207:00 amGNWDividend Declaration
13th Oct 20204:22 pmGNWOffer for Subscription
5th Oct 20207:00 amGNWSecond Interim Capital Dividend
5th Oct 20207:00 amGNWNAV Update
16th Sep 20207:00 amGNWInvestment Realisations and NAV
21st Aug 202010:55 amGNWChange of Registered Office
30th Jul 20207:00 amGNWHalf-year report
10th Jul 202011:43 amGNWIssue of Equity
24th Jun 202012:35 pmGNWB Share - Extension of Offer
13th May 20203:03 pmGNWPublication of a supplementary prospectus
29th Apr 202012:45 pmGNWIssue of Equity
29th Apr 20207:00 amGNWResult of Annual General Meeting
27th Apr 20206:52 pmGNWUpdate on Omega, Optibiotix and NAVs
20th Apr 20206:36 pmGNWOmega Diagnostics, Net Asset Value, New B Share Pool Investments
7th Apr 20204:35 pmGNWIssue of Supplementary Prospectus
3rd Apr 20202:10 pmGNWIssue of Equity
31st Mar 20205:30 pmGNWNet Asset Value(s)
26th Mar 20204:31 pmGNWAGM Venue Change
13th Mar 20204:14 pmGNWInterim Dividend
10th Mar 20202:28 pmGNWIssue of Equity
10th Mar 20207:00 amGNWB Share Net Asset Value
3rd Mar 20204:30 pmGNWIssue of Supplementary Prospectus
27th Feb 20207:00 amGNWFinal Results
9th Dec 20195:45 pmGNWDirectorate Change
27th Nov 20192:45 pmGNWIssue of Equity
20th Nov 20194:00 pmGNWDuplicate: Second Interim Dividend
28th Oct 20197:00 amGNWSecond interim dividend
10th Oct 20196:30 pmGNWDirector/PDMR Shareholding
10th Jun 20196:14 pmRNSResult of AGM
16th May 20197:00 amRNSSecond Interim Dividend
29th Apr 20198:52 amRNSFinal Results
25th Apr 20197:00 amRNSNet Asset Value(s)
5th Apr 201912:47 pmRNSIssue of Equity
3rd Apr 201912:46 pmRNSIssue of Equity
29th Mar 20195:20 pmRNSRevised timetable
13th Mar 201912:03 pmRNSExtension of Offer
7th Mar 20193:22 pmRNSIssue of Equity
6th Mar 201910:30 amRNSInterim Dividend

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.